This presentation is intended to allied health professional to have a overview of different types of insulin. It is meant to be a memory refresh. It was presented as part of continuing medical education session
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
A quick review of available insulin products
1. The Community Pharmacist’s Role in
Diabetes Management
2
Overview of Insulin
Products:
New Developments Review
Anas Bahnassi PhD RPh
2. This boy was
Leonard Thompson
Without insulin, this young
girl would have died in a
matter of days or weeks.
2
11/15/2013
Overview of insulin products - CE for Pharmacists
On January 11, 1922, at 14
years of age, A Canadian
boy from Toronto received
his first shot of insulin.
3. Patient is
diagnosed
with type
one
diabetes
Full day “conventional” coverage
Premixed insulin twice daily
Custom designed split mix variant
Full physiologic insulin coverage
Long acting analog at bedtime and
Rapid acting before meals
3
11/15/2013
Overview of insulin products - CE for Pharmacists
Possible Insulin Treatments
in Type-1 Diabetes:
4. Insulin use in type-2 diabetes
Overview of insulin products - CE for Pharmacists
• Start insulin if severe symptoms at time of diagnosis
or present with DKA.
• Pregnancy.
• Add insulin when antidiabetes medictions fail:
– Basal insulin is more cost effective than a
third oral agent.
– Insulin added to suboptimally controlled
patients on 2 oral antidiabetes medications
will result in A1C lowering by 1.5%.
4
11/15/2013
5. Type-2 diabetes evolving treatment
paradigm
-5
0
+5
+10
Amylin
Pramlintide
Diagnosis
Inhaled Insulin
Overview of insulin products - CE for Pharmacists
Years since diagnosis
-10
Insulin
Onset
GLP-1 Analogs and DPP-4
Inhibitors
Oral combotherapy
Oral
monotherapy
Diet and exercise
Pre-diabetes
Type-2 diabetes
5
11/15/2013
6. Percentage of patients advancing
when A1C >8%
66.6
When insulin was started, the average patient had:
• 5 years of A1C >8%
• 10 years of A1C >7%
44.6
35.5
18.8
Diet
Sulfonylurea
Metformin
Combination
6
11/15/2013
Overview of insulin products - CE for Pharmacists
Percentage
Brown JB et al. Diabetes Care (2004)
7. Barriers to insulin use
Physician resistance:
Compliance issues
Fears of scars
Administration difficulties
Lack of resources.
Time to plan and followup intensive therapy.
Perceived and real ADRs:
Weight gain, hypoglycemia
Optimal glycemic control requires
multiple daily injections.
7
11/15/2013
Overview of insulin products - CE for Pharmacists
Patient resistance:
8. Barriers to insulin use
All patients
High anxiety patients
Overview of insulin products - CE for Pharmacists
63
44
42
35
18
0
Troubled by the
idea of multiple
shots
11/15/2013
Avoid injection
due to anxiety
High anxiety
about injections
8
Zambanini A et al. Diabetes Res. Clin. Pract.(1999)
9. • Set appropriate goals
• Patient education
• Prudent assistance by others
• Use of premixed insulin
• Physiologic insulin treatment design
• Balance of food, activity, and insulin
• Injection devices
9
11/15/2013
Overview of insulin products - CE for Pharmacists
Overcoming patient obstacles
10. Physical and Chemical Properties
of Human Insulin
21 amino acids
α-chain
β-chain
Overview of insulin products - CE for Pharmacists
30 amino acids
Monomers
Dimers
Zn++
Zn++
Self-aggregation
in solution
Hexamers
(around Zn2+)
10
11/15/2013
11. The best insulin type for your
patient’s diabetes
•
•
•
•
•
•
Overview of insulin products - CE for Pharmacists
The best type of insulin for your patient
depends on many factors:
Individualized response to insulin
Lifestyle choices
Willing to use multiple injections daily
Frequency of glucose checking
Age
Blood glucose management goals
11
11/15/2013
12. Types of insulin
Rapid acting
Short acting
Intermediate acting
Long acting
Premixed
Overview of insulin products - CE for Pharmacists
•
•
•
•
•
12
11/15/2013
13. Rapid acting insulin
Duration Role in glucose
Brand
management
hr
Rapid-acting
Humalog or
15-30 30-90 3-5
insulin covers
lispro
insulin needs for
Novolog or
10-20 40-50 3-5
meals eaten at
aspart
the same time
as the injection.
This type of
Apidra or
insulin is often
20-30 30-90 1-2½
glulisine
used with
longer-acting
insulin.
13
11/15/2013
Overview of insulin products - CE for Pharmacists
Onset Peak
min min
17. Heinmann et al. Diabet. Med. 1996
Lys Pro
Asp
Lys
11/15/2013
Glu
Overview of insulin products
- CE for Pharmacists
17
18. Brand
Onset Peak
min hr
Regular (R)
humulin or 30-60 2-5
novolin
Velosulin
(for use in
30-60 2-3
the insulin
pump)
Duration Role in glucose
management
hr
Short-acting
5-8
insulin covers
insulin needs for
meals eaten
within 30-60
2-3
minutes
18
11/15/2013
Overview of insulin products - CE for Pharmacists
Short acting insulin
19. Intermediate acting insulin
NPH (N)
19
11/15/2013
Overview of insulin products - CE for Pharmacists
Brand
Duration Role in glucose
management
hr
Intermediateacting insulin
covers insulin
needs for about
half the day or
1-2
4-12 18-24
overnight. This
hours hours hours
type of insulin is
often combined
with rapid- or
short-acting
insulin
Onset Peak
min hr
21. Brand
Lantus
(insulin
glargine)
11/15/2013
Levemir
(insulin
detemir)
Duration Role in glucose
management
hr
Long-acting
insulin covers
insulin needs for
about one full
20-24
day. This type of
hours
insulin is often
combined, when
needed, with
rapid- or shortacting insulin
1-2
6-8
Up to 24
hours hours hours
21
Onset Peak
min hr
No
peak
time;
insulin
1-1½
is
hour
deliver
ed at a
steady
level
Overview of insulin products - CE for Pharmacists
Long acting insulin
22. Primary Structure of Gly(A21),
Arg(B31), Arg(B32)-Insulin
Leu
Glu
Asn
Tyr
Cys
Asn
16
17
18
19
20
21
Glargine
Leu
Glu
Asn
Tyr
Cys
Gly
Insulin
B-chain
Phe Tyr
Thr
Pro
Lys
Thr
25
26
27
28
29
Glargine
Phe Tyr
Thr
Pro
Lys
Overview of insulin products - CE for Pharmacists
Insulin
A-chain
30
Thr
Arg
Arg
22
11/15/2013
23. Primary Structure of Lys(B29)-N-Tetradecanoyl, Des(B30)-Insulin
Glu
Phe
Tyr
Thr
24
25
26
27
Gly
Glu
Phe
Tyr
Thr
Pro
28
Pro
Lys
29
Thr
30
Lys
Thr
(CH2)4
11/15/2013
• Fatty acid tail (myristic acid) added
to human insulin
• Complexes with albumin>20 hour
action
NH
CO
R
23
Overview of insulin products - CE for Pharmacists
Detemir
Gly
23
Insulin
24. Glucose infusion rates
(mg/kg/min)
6
NPH
5
4
Glargine
0.4 U/kg
3
2
Placebo
1
0
0
2
4
6
8
10 12 14 16 18 20 22 24 26 28 30
Time (h)
24
11/15/2013
Linkeschowa R, et al. Diabetes.1999;48(suppl 1):A97.
Overview of insulin products - CE for Pharmacists
Action Profiles of long acting
insulin analogs – Glargine
25. Action Profiles of long acting
insulin analogs – Detemir
1.5
1.0
Detemir - high
Detemir - low
0.5
Placebo
0.0
-100
100
300
500
700
900
1100
1300
1500
Overview of insulin products - CE for Pharmacists
Glucose infusion rate
(mg/kg/min)
2.0
Elapsed time (min)
25
11/15/2013
Brunner GA, et al. Exp Clin Endocrinol Diabetes. 2000;108:100-105.
27. Mixed vs. Basal Insulin Regimens
Analog mix
vs.
Human mix
Analog mix
vs. Long-acting
analogs
Analog mix
vs. “Other
regimens”
Strength of
Evidence
FPG
Similar
Favors longacting analog
Unknown
Moderate
PPG
Favors
analog mix
Favors analog
mix
Unknown
High
A1c Reduction
Similar
Favors analog
mix
Unknown
High
Hypoglycemia
Similar
Favors longacting analog
Unknown
High
Weight
Similar
Favors longacting analog
Unknown
Moderate
Mortality
Unknown
Unknown
Unknown
Unknown
Overview of insulin products - CE for Pharmacists
Outcome
27
11/15/2013
Qayyum R et al, Ann Intern Med 2008;149:549-559
28. • Determine who needs insulin
initiation
• Design a system that includes
the type of insulin that fits your
patient’s lifestyle
• Be ready to explain the
differences between types of
insulin
28
11/15/2013
Overview of insulin products - CE for Pharmacists
Sum-up
29. The Community Pharmacist’s Role in Diabetes Management
CE program for pharmacists
Anas Bahnassi PhD CDM CDE
abahnassi@gmail.com
http://www.twitter.com/abpharm
http://www.facebook.com/pharmaprof
http://www.linkedin.com/in/abahnassi